Boehringer

Home

Boehringer

Binger Str. 173
Ingelheim
55216

Tel: +49 / 6132 / 77 0
Fax: +49 / 6132 / 72 0
website: www.boehringer-ingelheim.com

Stroke is the second leading cause of death worldwide and a major cause of long-term disability.

More high-quality years of life are lost due to stroke than to any other disease. The disability caused by the disease can be significantly reduced by efficient treatment of those affected.

Stroke kills brain cells

A stroke occurs when a blood clot blocks a vessel or artery, or when a blood vessel breaks, interrupting blood flow to an area of the brain. When a stroke occurs, it kills brain cells in the immediate area. This can happen anytime from a few minutes after the stroke starts to a few hours later.

Stroke forum - dedicated to improving stroke therapy

Find out more on Boehringer Ingelheim's corporate website on stroke:Stroke forum

Products

Actilyse® (alteplase)
Indicated for thrombolytic treatment in acute ischaemic stroke.

Actilyse® is also registered for the indication acute myocardial infarction which can be found under "Acute Coronary Disease".

Aggrenox®, Asasantin®Retard (dipyridamole/ASA) Indicated to reduce the risk of stroke in patients who have had transient ischaemia of the brain or completed ischaemic stroke due to thrombosis.

Online Activities

Actilyse® - product website
International website (healthcare professionals)

Aggrenox/Asasantin® - product website
International website (healthcare professionals)

---

Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Our business consists largely of Human pharmaceuticals (consisting of Prescription Medicines, Consumer Health Care and Biopharmaceuticals) as well as Pharma Chemicals and Animal Health.

Keywords:

Boehringer Ingelheim, Ischaemic Stroke, Acute Coronary Disease, Acute Ischaemic Stroke, Stroke, Stroke Forum, Actilyse®, Actilyse®, Aggrenox®, Asasantin®Retard , Pharmaceuticals

Related categories: Pharmaceutical Companies

Products

These medicinal products require prescription either by primary care physicians or by specialists or form an integral part of hospital treatment. Branded Prescription Medicines, which represents the bulk of our Human Pharmaceuticals business, accounts for 79 % of our total net sales and generated in 2008 EUR 9,111 million (in local currencies).

Boehringer Ingelheim's product portfolio covers the following main indications:

• Acute Coronary Disease
• Benign Prostatic Hyperplasia
• Chronic Obstructive Pulmonary Disease (COPD)
• HIV/AIDS
• Hypertension
• Major Depressive Disorder (MDD)
• Parkinson's Disease
• Restless Legs Syndrome
• Stroke
• Thromboembolic Diseases

Just to mention a few of our other indications:

• generalised anxiety disorder
• diabetic peripheral neuropathic pain (DPNP)
• acute ischaemic stroke

Clinical Trials

Research & Development

Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.

• Our research & development comprises four major research & development sites and three support centres worldwide.
• During the past decade, Boehringer Ingelheim conducted or sponsored 1,223 studies with 125 substances in 58 countries from all regions of the world.
• We have more than 6,700 highly qualified people working in research & development out of 41,300 Boehringer Ingelheim employees worldwide.
• Our drug discovery focuses on seven major therapeutic areas: Cardiovascular Diseases, Central Nervous System Diseases (CNS), Immunology & Inflammation, Metabolic Diseases, Oncology, Respiratory Diseases, Virology.
• In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending more than 22% of net sales in its largest business segment Prescription Medicines on research and development.

Specialities:

Events: